Pinealon (circadian use)

Pinealon belongs to Khavinson's 'cytogen' series — very short synthetic peptides claimed to be tissue-specific epigenetic regulators. The proposed mechanism is direct: the tripeptide crosses cell and nuclear membranes and interacts with defined sequences in gene promoters, changing transcription of genes involved in antioxidant defence, apoptosis regulation and neuronal survival. Supporting work from the St Petersburg group includes cell-culture studies showing reduced oxidative damage and rodent work reporting preserved learning and reduced hypoxic injury. The circadian framing is largely by association — Pinealon is paired with Epitalon in pineal protocols and shares the same theoretical model — rather than by direct demonstration of a melatonin or clock-gene effect. Nothing here has been independently replicated outside the originating institute.

Targets: Neuronal gene promoter regions (proposed direct DNA binding), Antioxidant and anti-apoptotic gene expression, Cortical and pineal neurons

• · The Russian pharmacy product is a 10 mg capsule of peptide complex. Oral bioavailability of an intact tripeptide is effectively unmeasured, which is why the injectable dose is a hundred-fold lower.
• · This range comes from community and vendor protocols rather than any published trial. Some sources go as high as 1 to 2 mg daily, which has no better justification than the lower numbers.

Work out your exact syringe units →

• commonInjection-site redness or irritation— The most commonly reported effect.
• uncommonHeadache— Reported early in a course.
• uncommonDrowsiness or altered sleep timing— Sometimes the intended effect, sometimes not.
• uncommonMild gastrointestinal upset with the oral capsules— Attributable to the excipients as much as the peptide.

• Pregnancy and breastfeeding - no data.
• Active malignancy - the whole cytogen class is built on claims of altering gene transcription, and none of that has been characterised in cancer.
• Do not substitute it for evaluation of genuine cognitive decline; there is no evidence it treats anything diagnosable.

• synergyepitalon-circadian — The standard Khavinson pairing - Epitalon for the pineal, Pinealon for the neurons, run in the same course.
• cautiondsip — No data on the combination; the mechanisms do not obviously overlap, so any benefit is additive at best.
• redundantsemax — Overlapping neuroprotective and cognitive intent, with Semax having far more human data behind it.

• · No bloodwork is established. If cognition is the target, use a repeatable objective test rather than self-assessment.
• · Track sleep timing across a course if it is being used for circadian purposes.
• · Be honest with yourself about expectation effects here - this is a compound where the subjective report is doing almost all of the work.

Sold in Russia as a dietary-supplement-style peptide bioregulator. Not approved as a medicine in the US, UK or EU, where it is sold as a research chemical or an unregulated supplement.

• Khavinson et al., EDR peptide neuroprotection and antioxidant effects in neuronal culture (preclinical)
• Khavinson et al., Pinealon and cognitive preservation under hypoxia in rodents (preclinical)
• Ashapkin, Linkova & Khavinson, epigenetic mechanisms of short peptide bioregulators review (review)

Pinealon is the compound in this class where the gap between what is claimed and what has been shown is widest, and the record should say so plainly rather than dress a hypothesis in mechanistic language. The theoretical model is Khavinson's cytogen framework: very short synthetic peptides, two to four residues, that cross cell and nuclear membranes, interact with specific regions of gene promoters, and change transcription of genes in a tissue-specific way. Pinealon is the version aimed at neurons. The framework has some genuine experimental support - Fedoreyeva, Kireev, Khavinson and Vanyushin published fluorescence work in Biochemistry (Moscow) in 2011 showing short labelled peptides entering the nuclei of HeLa cells and interacting with deoxyribooligonucleotides and DNA in vitro, and the group has extended the same approach into plant systems, where short exogenous peptides altered expression of CLE, KNOX1 and GRF family genes in tobacco. So nuclear entry is not fabricated. What is missing is any demonstration that this is what produces a biological effect in an animal, and any replication from a laboratory not connected to St Petersburg. And the specificity problem is real and should not be waved away. Three residues carry very little information. A sequence-specific transcription factor typically recognises six to ten base pairs; a tripeptide cannot plausibly specify a unique genomic address in the way the marketing implies. The group's own more careful framing has moved toward effects on chromatin structure and on DNA methylation rather than classical sequence-specific binding, which is a more defensible claim and a much weaker one than what appears on vendor pages. The direct Pinealon evidence is thinner than the framework. Khavinson, Ribakova, Boldyrev and colleagues published in Rejuvenation Research in 2011 that Pinealon increased cell viability by suppressing free radical levels and activating proliferative processes - a cell culture antioxidant and viability result. Kozina and Arutiunian's in vitro work covers similar ground. There is rodent work from the same group reporting preserved learning and reduced injury under hypoxic stress, and cell culture work showing short peptides stimulating serotonin expression in cortical cells and restoring dendritic spine number in an in vitro Alzheimer's model. None of it is circadian. There is no melatonin measurement, no clock gene result, no sleep recording and no human trial of any size. Which means the circadian positioning is entirely by association. Pinealon is run alongside Epitalon in Khavinson protocols, shares the same theoretical model, and inherits Epitalon's melatonin story by proximity. Epitalon has small human trials reporting a melatonin effect. Pinealon has none. When someone tells you Pinealon is a circadian peptide, what they mean is that it comes in the same box as one. A final observation worth making because nobody makes it: EDR degrades to glutamate, aspartate and arginine. Glutamate is the principal excitatory neurotransmitter, aspartate is excitatory at NMDA receptors, and arginine is the substrate for nitric oxide synthase. Whether a 200 microgram dose of a tripeptide delivering those three amino acids does anything at all is doubtful on quantitative grounds - it is a vanishingly small amount against dietary and endogenous pools - but it is the mechanistically simplest explanation for any effect, and it has never been controlled for in the source literature.

The main thing that goes wrong with Pinealon is not harm, it is money and self-deception, and this is the compound on the site where that is most true. The expectation problem is the biggest one. Pinealon produces no acute sensation, has no measurable output, no established biomarker and no dose-response. There is nothing to tell you whether it is working except your own impression of your own cognition, which is exactly the measurement humans are worst at and most susceptible to expectation on. Add that it is almost always run inside a stack, during a period when someone has decided to take their health seriously and has also fixed their sleep and started exercising, and the attribution is hopeless. If you are going to run it, use a repeatable objective test with a numeric output, run at the same time of day, or accept that you are buying a feeling. The oral question is the second. The Russian capsule is 10 mg and the injectable community dose is 100 to 300 mcg. That hundred-fold gap is not a considered bioavailability adjustment - it is the absence of one. A free tripeptide taken orally faces gastric acid, pancreatic proteases and a brush border designed to reduce tripeptides to amino acids. Some intact absorption via PepT1 is possible. Nobody has measured it. An oral Pinealon capsule may be an expensive way to consume three amino acids. The third is dose drift. Community and vendor protocols range from 100 mcg to 2 mg daily by injection, and the higher numbers have no better justification than the lower ones - none of them come from a trial. When a compound's dose range spans twenty-fold with no data anywhere in it, that is a sign there is no dose-response curve to be on. The fourth is the continuous-use error, shared with the rest of the Khavinson family. The source protocols are 10 to 20 day courses repeated every three to six months. People buy a 20 mg vial and take it daily for months. There is no evidence base for that and no data on what continuous EDR exposure does. The fifth, and the only one with real downside: substituting Pinealon for evaluation of genuine cognitive decline. If your memory is measurably worse than it was two years ago, the things that need excluding are B12 deficiency, hypothyroidism, depression, obstructive sleep apnoea, medication effects and vascular disease - all common, several treatable, all missed if you decide it is age and buy a peptide. That delay is the actual harm this compound is capable of causing. The practical one: a 20 mg vial in 2 mL gives 10 mg/mL, which makes a 200 mcg dose 2 units on an insulin syringe. That is not a measurable volume with any accuracy. Use 4 to 5 mL of diluent if you are dosing in the low microgram range.

• No identified receptor — None established

  EDR is not proposed to be a ligand. There is no cloned receptor, no binding assay and no reported affinity for anything. The proposed mechanism is intracellular and transcriptional, which is why this section has nothing quantitative in it.

• Neuronal gene promoter regions and chromatin (proposed direct interaction) — Not characterised; no binding constant reported

  Proposed nuclear entry and interaction with DNA, supported by fluorescence and in vitro DNA-binding work on short peptides generally (Fedoreyeva et al. 2011) rather than on EDR specifically. Sequence specificity at three residues is not plausible in the classical transcription-factor sense, and the group's own framing has shifted toward chromatin-level effects.

• Antioxidant and anti-apoptotic gene expression — Not characterised

  Pinealon increased cell viability and suppressed free radical levels in culture, with activation of proliferative processes (Khavinson et al., Rejuvenation Research 2011). This is the most direct piece of evidence that exists for this specific peptide, and it is a cell culture result.

• Serotonin expression in cortical cells — Not characterised

  Short peptides from the cytogen series stimulated serotonin expression in brain cortex cells in culture (Khavinson et al., Bull Exp Biol Med 2014). Relevant to the mood and sleep framing, and in vitro.

• Pineal melatonin rhythm — Not characterised

  No evidence. Listed explicitly because it is the mechanism implied by selling this compound as circadian, and there is no melatonin measurement, clock gene result or sleep recording for Pinealon in any species.

• No controlled human trial of Pinealon exists None

  Stated explicitly because the absence is the central fact. Pinealon has no published randomised or controlled human trial of any size, and no human study measuring sleep, melatonin, circadian phase or cognition against a control. Its presence in sleep and circadian protocols rests on association with Epitalon rather than on its own data.

• Khavinson, Ribakova, Kulebiakin, Vladychenskaya, Kozina, Arutjunyan and Boldyrev - Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes (Rejuvenation Research 2011) Preclinical, cell culture · 2011

  Cell viability, free radical levels and proliferation in culture. The most direct published evidence for this specific peptide, and it is in vitro.

• Kraskovskaya, Kukanova, Linkova, Popugaeva and Khavinson - tripeptides restore the number of neuronal spines under conditions of in vitro modelled Alzheimer's disease (Bulletin of Experimental Biology and Medicine 2017) Preclinical, cell culture · 2017

  Dendritic spine number in an in vitro Alzheimer's model after cytogen tripeptides. Included because it is one of the better-designed pieces of the cytogen neuroprotection case, and because it is still cell culture.

Days 1 to 5: nothing acute. Pinealon produces no immediate sensation. Occasional injection-site redness, occasional early-course headache, occasional mild gastrointestinal upset with the oral capsules which is as likely to be the excipients as the peptide. Days 6 to 20: this is where reported effects, when reported at all, are said to emerge - subjective clarity, better sleep timing, less mental fatigue. All of it is self-report from uncontrolled use. There is no published human time course because there is no published human study. End of course: the Khavinson model holds that transcriptional changes persist after the peptide is gone, which is the justification for a 10 to 20 day course rather than continuous dosing. That persistence has never been measured for Pinealon in any species by any endpoint. Next course: 3 to 6 months later. Two or three courses a year is the standard pattern. The reason this section is vague is that it can only be vague. There is no biomarker, no acute effect, no dose-response and no controlled observation. A precise onset timeline for Pinealon would be fabricated.

Pinealon exists almost entirely as half of a pair, and the honest advice is about attribution rather than synergy. With Epitalon: the standard Khavinson pineal course. Both run for 10 to 20 days, Epitalon aimed at the gland and Pinealon at the neurons. This is how the source protocols do it and there is nothing dangerous about it. What there is, is an attribution problem you should be deliberate about: Epitalon has small human trials reporting a melatonin effect and Pinealon has none, so if you run both and something happens, the prior overwhelmingly favours Epitalon. If you want to know whether Pinealon does anything for you, run one course of Epitalon alone and one course of the pair, months apart, with aMT6s measured around both. Almost nobody does this, which is why the compound's reputation has survived intact. With Thymalin: the third leg of the classic Khavinson geriatric protocol. Same comment applies. With DSIP: no data, no obvious mechanistic overlap, and no reason to expect more than additive effects at best. DSIP is acting tonight and Pinealon is claiming to act on transcription over weeks. With Semax: overlapping neuroprotective and cognitive intent, and Semax has vastly more human data behind it - it is a registered medicine in Russia with clinical trials in stroke and cognitive impairment. If the goal is cognition and you are choosing between the two, that is not a close call. With an oral cytogen stack - Pinealon plus Vesugen plus Cortagen and so on: this is where the category gets sold hardest and evaluated least. Each additional compound multiplies cost and divides your ability to attribute anything. Run one at a time or accept you will never know. What actually pairs with it for the stated goal: morning bright light, a fixed wake time, aerobic exercise and adequate sleep are the interventions with real evidence for age-related cognitive and circadian decline. They are also the ones nobody sells.

Against Epitalon: not a close comparison for a circadian goal. Epitalon has small human trials reporting restored nocturnal melatonin in elderly subjects and old monkeys. Pinealon has cell culture and rodent work and no circadian measurement of any kind. If you are choosing one Khavinson peptide for sleep or rhythm, it is Epitalon. Against Semax: for a cognitive goal, Semax is the better-evidenced compound by a wide margin - a registered medicine in Russia with clinical trials in stroke and cognitive impairment, a characterised mechanism including enkephalinase inhibition and BDNF effects, and far more published work outside the originating institute. Pinealon's cognitive case is cell culture and hypoxia models. Against Cerebrolysin: another Eastern European neuroprotective preparation, and one with a substantially larger clinical literature including Cochrane-level review attention in stroke and dementia (with mixed and often unfavourable conclusions, but at least the evidence exists to be reviewed). Pinealon has nothing of the kind. Against nothing: the comparison that should be made and rarely is. For age-related cognitive and circadian decline, the interventions with real evidence are aerobic exercise, treating hearing loss, controlling blood pressure, treating sleep apnoea, morning light exposure and a fixed sleep schedule. Every one of them has better evidence than Pinealon and most are free. If those are not in place, buying a tripeptide is optimising the wrong variable. Within the cytogen family: Pinealon is one of a series - Vesugen, Cortagen, Testagen and others - all built on the same theoretical model, all from one institute, all with the same evidence structure. If the model is right, it is right for all of them; if it is not, none of them work. Buying several is not diversification, it is the same bet placed repeatedly. What Pinealon has going for it: it is cheap, it appears to be safe across the Russian experience, it comes from a group doing real if unreplicated laboratory work, and the underlying question - whether very short peptides can act as transcriptional regulators - is a genuinely interesting one. That is a fair description of a low-cost, low-expectation experiment. It is not a description of a circadian intervention.

$15–$60/month. A 20 mg injectable vial covers a full 10 to 20 day course at community doses many times over and typically sells in the low-to-mid double-digit dollar range on the research-chemical market. Russian pharmacy capsules are usually sold as a 20-capsule course box at a comparable price. Amortised across two or three courses a year this lands in the region of 15 to 60 dollars a month. Indicative retail observations, not sourced or surveyed pricing.

• ?There is no controlled human trial of Pinealon of any size, and no human study measuring sleep, melatonin, circadian phase or cognition against a control.
• ?There is no direct evidence of any circadian or melatonin effect for Pinealon in any species. Its placement in circadian protocols is by association with Epitalon.
• ?No pharmacokinetic data exists in any species - no tmax, no bioavailability, no clearance, no brain penetration measurement.
• ?Whether oral EDR is absorbed intact in humans is unknown. Absorption of tripeptides via PepT1 is possible in principle but has not been demonstrated for this peptide.
• ?The hundred-fold difference between the 10 mg oral capsule and the 100 to 300 mcg injectable dose has no measured basis.
• ?The injectable dose range in circulation spans roughly 100 mcg to 2 mg daily with no data supporting any point in it.
• ?The proposed mechanism of promoter binding by a tripeptide is not straightforwardly plausible on information-content grounds. The supporting nuclear-entry and DNA-interaction work (Fedoreyeva et al. 2011) was done on short peptides generally rather than on EDR specifically.
• ?No independent replication of any cytogen finding outside the Khavinson group and associated St Petersburg institutions could be identified.
• ?Whether the claimed persistence of transcriptional effects after a course ends is real has never been measured for this peptide.
• ?The possibility that any observed effect is attributable to the constituent amino acids - glutamate, aspartate and arginine - rather than the intact tripeptide has not been controlled for in the source literature.
• ?The rodent hypoxia and learning-preservation work attributed to Pinealon was not individually verified to a specific primary citation in this session; the citations listed are the ones I resolved.
• ?The 418.4 Da molecular weight was confirmed by calculation from the EDR sequence rather than from a cited analytical measurement.
• ?The composition of the Russian pharmacy capsule product - whether it is synthetic EDR, a peptide complex, or a tissue extract - is not consistently stated across sources and may differ from the injectable research-chemical product.
• ?Cost figures are indicative retail observations, not sourced or surveyed data.

• Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A, Rejuvenation Research, 2011 · PMID 21978084

  Rejuvenation Res 14(5):535-41. The primary Pinealon-specific paper, in English, in a peer-reviewed Western journal. Cell culture. If you want to evaluate this compound on its own evidence rather than Epitalon's, this is where you start and very nearly where you finish.

• Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease Kraskovskaya NA, Kukanova EO, Linkova NS, Popugaeva EA, Khavinson VK, Bulletin of Experimental Biology and Medicine, 2017 · PMID 28853087

  Bull Exp Biol Med 163(4):550-553. Cytogen tripeptides restoring dendritic spine number in an in vitro Alzheimer's model.

• Short peptides stimulate serotonin expression in cells of brain cortex Khavinson VKh, Linkova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO, Bulletin of Experimental Biology and Medicine, 2014 · PMID 24909721

  Bull Exp Biol Med 157(1):77-80. The closest thing to a mood or sleep mechanism in the cytogen literature, and it is in cortical cell culture.

• Biological activity of regulatory peptides in model experiments in vitro Kozina LS, Arutiunian AV, Stvolinsky SL, Khavinson VKh, Advances in Gerontology, 2008 · PMID 18546826

  Adv Gerontol 21(1):68-73. The in vitro antioxidant characterisation of the cytogen peptides.

• Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture Khavinson VKh, Linkova NS, Chalisova NI, Dudkov AV, Koncevaya EA, Bulletin of Experimental Biology and Medicine, 2011 · PMID 22803060

  Bull Exp Biol Med 152(1):138-41. Short peptides acting on pineal tissue in organotypic culture - the closest the cytogen literature gets to a pineal mechanism, and still not a circadian measurement.

• Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF, Biochemistry (Moscow), 2011 · PMID 22117547

  Biochemistry (Mosc) 76(11):1210-9. The experimental basis for the nuclear entry and DNA interaction claim that the entire cytogen model rests on.

• Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum Fedoreyeva LI, Dilovarova TA, Ashapkin VV, Martirosyan YT, Khavinson VK, Kharchenko PN, Vanyushin BF, Biochemistry (Moscow), 2017 · PMID 28371610

  Biochemistry (Mosc) 82(4):521-528. Included because it is genuinely interesting and rarely cited by vendors: the same short peptides alter gene expression in tobacco plants. That either strengthens the case for a fundamental chromatin-level mechanism or undermines the case for tissue-specific targeting in humans, depending on how you read it. Worth reading both ways.

• Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats Voicekhovskaya MA, Chalisova NI, Kontsevaya EA, Ryzhak GA, Bulletin of Experimental Biology and Medicine, 2012 · PMID 22803085

  Bull Exp Biol Med 152(3):357-9. Representative of the wider cytogen tripeptide literature and its methodology - organotypic culture, age-comparison design, single institute.